315 related articles for article (PubMed ID: 9523521)
1. Cytokines in inflammatory bowel disease.
Rogler G; Andus T
World J Surg; 1998 Apr; 22(4):382-9. PubMed ID: 9523521
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the mucosal immune system in inflammatory bowel disease.
MacDermott RP
J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
4. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
van Hogezand RA; Verspaget HW
Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.
Lv QK; Liu JX; Li SN; Gao YJ; Lv Y; Xu ZP; Huang BX; Xu SY; Yang DX; Zeng YL; Liu DF; Wang W
Int J Mol Sci; 2015 Nov; 16(11):26654-66. PubMed ID: 26561804
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines.
Gay J; Kokkotou E; O'Brien M; Pothoulakis C; Karalis KP
Neuroimmunomodulation; 2006; 13(2):114-21. PubMed ID: 17077645
[TBL] [Abstract][Full Text] [Related]
7. Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.
Andus T; Daig R; Vogl D; Aschenbrenner E; Lock G; Hollerbach S; Köllinger M; Schölmerich J; Gross V
Gut; 1997 Nov; 41(5):651-7. PubMed ID: 9414973
[TBL] [Abstract][Full Text] [Related]
8. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease.
Schreiber S; Heinig T; Panzer U; Reinking R; Bouchard A; Stahl PD; Raedler A
Gastroenterology; 1995 Jan; 108(1):21-33. PubMed ID: 7806044
[TBL] [Abstract][Full Text] [Related]
9. [Cytokines in the pathogenesis of inflammatory bowel diseases].
José León A; Garrote JA; Arranz E
Med Clin (Barc); 2006 Jun; 127(4):145-52. PubMed ID: 16831396
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation.
Scheibe K; Kersten C; Schmied A; Vieth M; Primbs T; Carlé B; Knieling F; Claussen J; Klimowicz AC; Zheng J; Baum P; Meyer S; Schürmann S; Friedrich O; Waldner MJ; Rath T; Wirtz S; Kollias G; Ekici AB; Atreya R; Raymond EL; Mbow ML; Neurath MF; Neufert C
Gastroenterology; 2019 Mar; 156(4):1082-1097.e11. PubMed ID: 30452921
[TBL] [Abstract][Full Text] [Related]
11. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum.
Rogy MA; Beinhauer BG; Reinisch W; Huang L; Pokieser P
Hum Gene Ther; 2000 Aug; 11(12):1731-41. PubMed ID: 10954907
[TBL] [Abstract][Full Text] [Related]
12. The pentacyclic triterpene Lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease.
Zhu Y; Li X; Chen J; Chen T; Shi Z; Lei M; Zhang Y; Bai P; Li Y; Fei X
Int Immunopharmacol; 2016 Jan; 30():74-84. PubMed ID: 26655877
[TBL] [Abstract][Full Text] [Related]
13. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization?
Shen C; de Hertogh G; Bullens DM; Van Assche G; Geboes K; Rutgeerts P; Ceuppens JL
Inflamm Bowel Dis; 2007 Mar; 13(3):308-16. PubMed ID: 17206708
[TBL] [Abstract][Full Text] [Related]
14. [The cytokines in inflammatory bowel disease].
Polińska B; Matowicka-Karna J; Kemona H
Postepy Hig Med Dosw (Online); 2009 Aug; 63():389-94. PubMed ID: 19724079
[TBL] [Abstract][Full Text] [Related]
15. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings.
Yamamoto T; Saniabadi AR; Umegae S; Matsumoto K
Inflamm Bowel Dis; 2006 Aug; 12(8):719-26. PubMed ID: 16917227
[TBL] [Abstract][Full Text] [Related]
16. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease.
Hyams JS; Fitzgerald JE; Wyzga N; Muller R; Treem WR; Justinich CJ; Kreutzer DL
J Pediatr Gastroenterol Nutr; 1995 Nov; 21(4):419-25. PubMed ID: 8583293
[TBL] [Abstract][Full Text] [Related]
17. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
[TBL] [Abstract][Full Text] [Related]
18. Mucosal cytokine network in inflammatory bowel disease.
Andoh A; Yagi Y; Shioya M; Nishida A; Tsujikawa T; Fujiyama Y
World J Gastroenterol; 2008 Sep; 14(33):5154-61. PubMed ID: 18777592
[TBL] [Abstract][Full Text] [Related]
19. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory mediators in chronic inflammatory bowel diseases.
Gross V; Andus T; Leser HG; Roth M; Schölmerich J
Klin Wochenschr; 1991 Dec; 69(21-23):981-7. PubMed ID: 1798295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
